Darolutamide now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ...
Clinicopathological features and genomic profiles of prostate cancer with elevated carbohydrate antigen 19-9. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does ...
OXFORD, England & MONROE TOWNSHIP, N.J.--(BUSINESS WIRE)--Blue Earth Diagnostics Ltd, a Bracco company and recognised leader in the development and commercialisation of innovative PET ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback